1. Home
  2. FIVN vs AGIO Comparison

FIVN vs AGIO Comparison

Compare FIVN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$15.71

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.80

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIVN
AGIO
Founded
2001
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
FIVN
AGIO
Price
$15.71
$27.80
Analyst Decision
Buy
Buy
Analyst Count
19
8
Target Price
$26.32
$37.63
AVG Volume (30 Days)
2.7M
708.3K
Earning Date
05-21-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
364.71
N/A
EPS
0.45
N/A
Revenue
$1,149,088,000.00
$43,011,000.00
Revenue This Year
$11.39
$75.68
Revenue Next Year
$10.00
$167.63
P/E Ratio
$36.13
N/A
Revenue Growth
10.28
N/A
52 Week Low
$15.70
$22.24
52 Week High
$31.75
$46.00

Technical Indicators

Market Signals
Indicator
FIVN
AGIO
Relative Strength Index (RSI) 36.61 46.37
Support Level N/A $26.48
Resistance Level $20.04 $29.49
Average True Range (ATR) 0.90 1.13
MACD -0.17 -0.17
Stochastic Oscillator 0.00 25.09

Price Performance

Historical Comparison
FIVN
AGIO

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: